Home > Riviste > Minerva Medica > Fascicoli precedenti > Minerva Medica 2021 April;112(2) > Minerva Medica 2021 April;112(2):228-37

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

REVIEW  HEPATITIS C INFECTION: A SYSTEMIC DISEASE 

Minerva Medica 2021 April;112(2):228-37

DOI: 10.23736/S0026-4806.20.07208-0

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Hepatitis C: clinical management and debated issues

Stefano GITTO 1, Carmela CURSARO 2, Alessandra BARTOLI 2, Marzia MARGOTTI 2, Pietro ANDREONE 2

1 Unit of Internal Medicine and Liver, University Hospital Careggi, Florence, Italy; 2 Unit of Internal and Metabolic Medicine, University Hospital of Modena, University of Modena and Reggio Emilia, Modena, Italy



Hepatitis C virus represents an important global health issue with 71 million of infected people in the word. Direct-acting antivirals are quite new molecules that hit specific Hepatitis C virus proteins useful for viral replication and assembly. Notably, Direct-acting antivirals bring to high sustained virological response rates showing also a great safety profile. This treatment revolution had an impact on transplantation world, in fact the number of liver transplants due to Hepatitis C virus-related cirrhosis and hepatocellular carcinoma is quickly decreasing. Even if this therapy has achieved excellent results in terms of morbility and mortality rates’ reduction, there are some debated issues to consider. In the present review the main clinical challenges in every-day management of Hepatitis C virus patients treated with Direct-acting antivirals and the debated effects of viral clearance (metabolic, cardiovascular, immunologic and neoplastic) are discussed. The detection of barriers that can preclude the delivery of Hepatitis C virus care, is the most complex challenge for the scientific community. To obtain the Hepatitis C virus global eradication by 2030, as the World Health Organization has set, will be complex and laborious and will need a further multilevel effort.


KEY WORDS: Hepatitis C; Hepatitis C, chronic; Antiviral agents

inizio pagina